Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway
- Ikiru Atsuta†1, 2,
- Shiyu Liu†1, 3,
- Yasuo Miura4,
- Kentaro Akiyama1, 5,
- Chider Chen1,
- Ying An3, 6,
- Songtao Shi†1, 3Email author and
- Fa-Ming Chen†3, 6Email author
© Atsuta et al.; licensee BioMed Central Ltd. 2013
Received: 27 May 2013
Accepted: 6 September 2013
Published: 11 September 2013
Cell-based therapy represents a new frontier in the treatment of a wide variety of human diseases traditionally associated with morbidity outcomes, including those involving inflammation, autoimmunity, tissue damage, and cancer. However, the use of mesenchymal stem cells (MSCs) to treat multiple myeloma (MM) bone disease has raised concerns. Specifically, evidence has shown that infused MSCs might support tumor growth and metastasis.
In this study, we used a standard disseminated MM model in mice to identify the in vivo effects of intravenous MSC infusion. In addition, a series of in vitro co-culture assays were preformed to explore whether Fas/Fas ligand (Fas-L) is involved in the inhibitory effects of MSCs on MM cells.
In the MM mouse model, treatment of MSCs with highly expressed Fas ligand (Fas-Lhigh MSCs) showed remarkable inhibitory effects on MM indenization in terms of extending the mouse survival rate and inhibiting tumor growth, bone resorption in the lumbus and collum femoris, and MM cell metastasis in the lungs and kidneys. In addition, reduced proliferation and increased apoptosis of MM cells was observed when co-cultured with Fas-Lhigh MSCs in vitro. Furthermore, mechanistically, the binding between Fas and Fas-L significantly induced apoptosis in MM cells, as evidenced through an increase in the expression of apoptosis marker and Fas in MM cells. In contrast, Fas-Lnull MSCs promote MM growth.
These data suggest that Fas/Fas-L-induced MM apoptosis plays a crucial role in the MSC-based inhibition of MM growth. Although whether MSCs inhibit or promote cancer growth remains controversial, the levels of Fas-L expression in MSCs determine, at least partially, the effects of MSCs on MM cell growth.
Multiple myeloma (MM) is the second most common hematological malignancy, with a yearly incidence of 14,000 in the United States, constituting 13% of blood cancers and 1% of all human cancers . MM is unique among most hematological malignancies, with a high capacity to induce osteolytic bone lesions through the suppression of osteoblastogenesis, stimulation of osteoclastogenesis and the subsequent uncoupling of bone resorption and bone formation in areas adjacent to tumor foci in the bone marrow . The occurrence of bone lesions is thus one of the major characteristics of MM patients ; the number of osteolytic or focal lesions has been associated with clinical disease progression for patients with MM . More than 80% of MM patients suffer from large osteolytic lesions, and a lack of clinically effective therapeutics leads to the increasing severity of skeletal complications and, indeed, death as a result of lowered resistance to infection (that is, immunodeficiency), hypercalcemia, anemia, and renal failure, among others . It is estimated that MM, with a median overall survival of 3 to 5 years, accounts for approximately 20% of deaths from hematologic malignancy and 1 to 2% of cancer-related deaths overall . Currently, cure is a realistic goal for only a small minority of MM patients. The high morbidity and mortality rates associated with plasma cell malignancy have led to an increased demand for the effective management of this condition.
It is now generally accepted that MM bone disease is a reflection of osteoblast deactivation [3, 7]. The correction of osteoblast function in the bone of MM patients, therefore, has long been a primary target for the design of therapeutics for MM-related bone disease. To this end, bisphosphonates, such as pamidronate, and novel agents, such as lenalidomide, dasatinib, and bortezomib, which inhibit osteoclast activity and/or activate osteoblasts, have been identified for treatment of MM-induced osteoblast deactivation [2, 8]. Increased knowledge of the signaling pathways involved in the regulation of osteoblast formation and differentiation from MSCs might provide a better understanding of the pathophysiological mechanisms involved in MM-induced osteoblast inhibition and permit the development of more potential therapeutic agents against bone damage [2, 8, 9]. In this regard, novel osteoblast-activating agents, such as dickkopf-1-neutralizing antibody  and inhibitor of activin A signaling , are explored for the clinical treatment of MM bone disease. The combination of traditional cytotoxic and novel agents has led to higher response rates and improved long-term survival compared with treatment with standard doses of chemotherapy alone. Unfortunately, not all patients will respond to established novel agents, and even those who do respond will ultimately relapse or become refractory to currently available regimens. Moreover, large lytic lesions are typically not repaired, even after long-term remission, and relapses often occur in pre-existing lesions . Consequently, additional approaches are urgently needed to achieve systemic bone anabolism and repair large osteolytic lesions.
The use of mesenchymal stem cells (MSCs), also called mesenchymal stem cells, to treat MM bone disease has received considerable attention in the field of stem cell research . However, whether MSC infusion inhibits or promotes cancer growth remains controversial. A number of in vitro studies suggest that MSCs from MM patients possess abnormal genomic, phenotypic, and functional properties, which might contribute to impaired bone formation in this disease by supporting and protecting MM cells from spontaneous and drug-induced apoptosis . Furthermore, recent evidence shows that MSCs, when injected subcutaneously, promote tumor growth and neovascularization in syngeneic mouse models through directly supporting the tumor vasculature and secreting proangiogenic factors . Indeed, the promotion of tumor growth through MSCs has also been observed in various cancer models (reviewed in ), suggesting that, at least in some specific conditions, MSCs play important roles in tumor progression. In contrast with evidence supporting the fact that MSCs stimulate tumor growth, other studies have documented the routine suppression of tumor growth through MSCs (also reviewed in ). In particular, exogenously administered MSCs effectively promote bone formation and inhibit bone disease and the growth of highly aggressive MM cells in the bone, although the majority of systemically injected MSCs were localized in the lungs or in draining lymph nodes . Furthermore, intrabone-injected MSCs have been demonstrated to act as bystander cells to promote bone formation, inhibit osteolysis, and delay MM growth and regrowth [5, 15]. New insights into the effects of in vivo milieu on MSC functions might explain these contradicting results [16, 17]. Notably, a high dose of melphalan with autologous stem cell support has played an integral part in MM therapy for more than 25 years, either as salvage therapy or to consolidate initial remission, although these therapeutic regimens typically utilize MM cells as adjuvants for other therapeutic agents . Moreover, after MSC transplantation in over 1,000 patients with a clinically acceptable safety profile, not a single case of MSC-related tumors has been reported in a variety of indications . Conceptually, it is a small leap from the adjuvant use of stem cells to novel cell-based therapies to enhance the therapeutic outcome of MM, but the idea has only recently begun to gain momentum.
The clinical and molecular characteristics of MM-related osteolytic lesions support the potential success of cell-based therapies for this disease [5, 12, 15], where the exogenous administration of healthy MSCs might affect MM bone disease via the secretion of trophic factors, instead of, or in addition to, directly participating in the regeneration of the damaged bone . Gunn and colleagues showed that an interaction between MM cells and MSCs from the bone marrow stroma stimulated the production of dickkopf-1 and IL-6, resulting in the formation and persistence of osteolytic bone lesions . These authors also showed that the Wnt signaling activator 6-bromoindirubin-3′-monoxime might release MSCs from the osteoinhibitory effects of Dickkopf-1, enabling released MSCs to repair existing osteolytic lesions . Following the adjuvant use of stem cells for MM therapy , Li and colleagues proposed a proof-of-concept that healthy MSCs, independent of other therapeutic agents, might attenuate the growth of MM and suppress MM-induced bone disease through the inhibition of osteoclastogenesis and stimulation of endogenous osteoblastogenesis [5, 15]. Taken together, these data lead to new insights into, and the further exploration of, stem cell-based therapeutics for MM patients.
In addition to altering the bone marrow milieu that favors MM cell accommodation, the therapeutic effects of exogenously infused MSCs might also root from healthy MSC-induced MM cell death/apoptosis . However, the underlying crosstalk between MSCs and MM cells in vitro and in vivo remains unknown. The execution of programmed cell death is a process triggered through many factors, such as radiation, chemotherapeutic drugs, and apoptotic signaling, which occurs via intrinsic and extrinsic pathways. Both pathways stimulate an intracellular cascade of events leading to cell death. The intrinsic pathway is initiated by mitochondria, whereas the extrinsic pathway is activated through death receptors that engage their respective ligands on the surface membrane of target cells. Fas (DR2/CD95/Apo-1) is a type I cell membrane protein with an extracellular domain that binds Fas ligand (Fas-L) and a cytoplasmic domain that transduces the death signal [19, 20]. Fas-L (CD95L/CD178/Apo-1 L) is a type II cell membrane protein belonging to the TNF family, which is inducibly expressed in lymphocytes and constitutively expressed in cells present in immune-privileged organs [21, 22]. Fas-L interacts with its receptor, Fas, triggering a cascade of subcellular events culminating in apoptotic cell death . Although Fas/Fas-L interactions play an important role in inducing cell apoptosis, it remains unclear whether Fas/Fas-L is involved in the inhibitory effects of exogenously infused MSCs on MM cells. The purpose of the present study was therefore to determine whether MSCs exert apoptosis-inducing effects on MM cells in vitro and in vivo through altering Fas/Fas-L expression.
Materials and methods
Multiple myeloma cell line
The 5TGM1 MM cell line used in the present study was subcloned from a stroma-independent cell line originally established from parent murine 5 T33 (IgG2bκ) MMs  and grown in long-term suspension culture in Isocove’s modified Dulbecco’s medium (Invitrogen Co., Carlsbad, CA, USA) with 10% fetal bovine serum (Summit Biotechnology, Fort Collins, CO, USA) and antibiotics. In the tracing experiment, MM cells were stained with carboxyfluorescein diacetate, succinimidyl ester (Invitrogen Co.).
Isolation of bone marrow mesenchymal stem cells
Bone marrow cells were flushed from the bone cavity of femurs and tibias of B6 mice (C57BL/6 J) with 2% heat-inactivated fetal bovine serum (Equitech-Bio, Kerrville, TX, USA) in PBS, and MSCs positive for CD73, CD90, CD105, CD146, CD166, Sca-1 and SSEA-4, but negative for CD11b, CD31, CD34 and CD45, were obtained as previously described . The cells with MSC character were cultured with alpha minimum essential medium (Invitrogen) supplemented with 20% fetal bovine serum and 2 mM l-glutamine (Invitrogen) in a humidified atmosphere of 95% air and 5% CO2 at 37°C for 3 days before co-culture . Additionally, MSCs, which had no Fas-L, were isolated from generalized lymphoproliferative disease (gld) mice for use in comparative experiments. B6 and gld mice in the same background (B6Smn.C3-Faslgld/J) were purchased from the Jackson Laboratory.
5TGM1 multiple myeloma model and MSC administration
Microcomputed tomography analysis
The cross-sectional volumetric bone mineral density was measured in right femur diaphysis of the mice in each group after 4 weeks of feeding (for each group, n = 6). High-resolution whole-body radiographs of ketamine-anesthetized mice were obtained with the Inveon microcomputed tomography system (Siemens AG, Bensheim, Germany). Using two-dimensional images, a region of interest in secondary spongiosa was manually drawn near the endocortical surface, and cancellous bone morphometric parameters including the bone volume relative to the tissue volume (percentage) and the trabecular thickness (millimeters) were assessed. A trained observer blinded to the composition of the different groups and treatments received analyzed the number and surface area of radiolucent lesions.
Tissue preparation and immunohistochemistry
Tissue preparation was performed as previously described . The mice were sacrificed after 4 weeks of feeding. The samples were immersed in 4% paraformaldehyde for 24 hours and embedded in 20% sucrose overnight at 4°C. The samples were immersed in O.C.T. compound (Sakura, Tokyo, Japan) for 2 hours at 4°C and cut into 6 μm thick bucco-palatal sections using a cryostat at −20°C. For immunofluorescence staining, the sections were blocked for 30 minutes with 10% normal goat serum and incubated overnight with fluorescein isothiocyanate-conjugated polyclonal rabbit Sca-1 IgG (1:100; Vector Laboratories, Burlingame, CA, USA), 7AAD and Annexin V (Apoptosis Detection Kit; BD Biosciences, Franklin Lakes, NJ, USA) at 4°C. The other sections were stained with hematoxylin and eosin and photographed using a light microscope. In addition, for terminal deoxynucleotidyl transferase-mediated UTP nick-end labeling (TUNEL), an apoptosis detection kit (Millipore Co., Billerica, MA, USA) was used in accordance with the manufacturer’s instructions.
Cell culture conditions
To determinate the in vitro cellular effects of MSCs on MM and 5TGM1 MM cells were co-cultured with MSCs directly or under Transwell® culture conditions. For direct co-culture, MM cells were plated at 5 × 105/ml with or without 5 × 105/ml MSCs for 0, 6, 12 or 24 hours. For in-direct co-culture, Transwell® culture was used. Briefly, the upper chamber (0.5 ml culture medium) contained 0.5 × 105 MSCs, and the bottom chamber (1.5 ml medium) contained either the same number or 5 to 10 times that of MM cells. The Transwell® culture without MSCs in the upper chamber served as the control. In the conditioned culture medium, 0.5 × 105 MSCs were cultured for 3 days. The supernatant was harvested, added to the MM cultures, and then cultured for 0, 6, 12 or 24 hours.
Flow cytometric analysis
After the MM cells were co-cultured with MSCs for 0, 6, 12 and 24 hours under Transwell® culture conditions, the cells were harvested, washed in PBS and incubated with Annexin-V– fluorescein isothiocyanate and 7AAD-PerCP for 15 minutes at room temperature in the dark. Apoptosis was analyzed on a BD FACSCalibur™ flow cytometer (BD Biosciences, San Jose, CA, USA), as described in the literature .
Total cell lysates for western blots were prepared after lysing cell pellets in radioimmunoprecipitation assay buffer. The lysates were separated through 7.5% SDS-PAGE, transferred to Immobilon™-P nitrocellulose membranes (Millipore, Inc.) and immunoblotted with Fas (1:100) or Fas-L (1:100) antibodies at 4°C overnight. The membranes were subsequently incubated with horseradish peroxidase-conjugated anti-rabbit IgG (1:10,000; Santa Cruz Biosciences, Santa Cruz, CA, USA) for 1 hour, followed by enhancement with a SuperSignal® West Pico Chemiluminescent Substrate (Thermo, Rockford, IL, USA). The bands were detected on BIOMAX MR film (Kodak, Rochester, NY, USA). Each membrane was also stripped using a stripping buffer (Thermo) and reprobed with anti-β-actin antibody to quantify the amount of loaded protein.
Immunofluorescence staining for multiple myeloma cells or MSCs
MM cells and MSCs co-cultured on dishes were fixed in 4% formaldehyde for 10 minutes. For fluorescence staining, the samples were treated in 0.5% (V/V) Triton X-100 (Novocastra Laboratories Ltd, Newcastle, UK) for 3 minutes and incubated with Annexin V/7AAD. The other cells were blocked with 10% normal goat serum for 30 minutes at 37°C and incubated overnight at 4°C with anti-Fas (1:100; Chemicon International Inc. Temecula, CA, USA) or anti-Fas-L (1:100; Chemicon International Inc.) antibodies. The samples were incubated with tetramethylrhodamine isothiocynate-conjugated or fluorescein isothiocyanate-conjugated secondary antibodies for 2 hours at 37°C. Imaging was performed using an Axiotech Microscope (Carl Zeiss Co. Ltd, Göttingen, Germany).
Data are expressed as mean ± standard deviation for two to four parallel experiments repeated separately. One-way analysis of variance and Fisher’s least-significant difference tests were performed. P <0.05 was considered statistically significant. The experiments were performed in triplicate and repeated twice or more to verify the results.
Effects of MSC infusion on multiple myeloma model mice
We investigated the 6-week survival rates of mice in each group (for each group, n = 14). The effect of MSC administration on the 6-week survival rates of MM model mice is shown in Figure 1B. The survival rate of MM model mice without MSC or L-PAM treatment (MM group) dramatically decreased until all mice died after 6 weeks of feeding. MM model mice with MSC (MSC group) or L-PAM (L-PAM group) administration showed no difference in the survival rate during the 6-week observation period (P >0.05). Although the survival rate of mice in the MSC group or the L-PAM group was lower than in the Control group (original nude mice without MM cell injection) (P <0.05), the administration of either MSCs or L-PAM achieved prolonged survival compared with the MM group (P <0.05). No animal in the negative control group died (the original nude mice without any treatments) after 6 weeks of feeding.
The number and size of cancroid pearls were compared among the four groups (for each group, n = 14) after 4 weeks of feeding (Figure 1C). No cancroid pearls were identified in the negative control group (Control group), but significant differences in the number and size of the pearls were observed between the MSC and MM groups (P <0.05). Although the number of pearls showed no significant difference, the size of the pearls in the L-PAM group was smaller compared with the MM group (P <0.05). These data indicate that MSC administration inhibits both the number and the size of cancroid pearls in MM model mice, while L-PAM administration inhibits only the size of cancroid pearls.
Furthermore, bone resorption in the lumbus and collum femoris of mice in different groups was examined and statistically analyzed through microcomputed tomography after 4 weeks of feeding (for each group, n = 3) (Figure 1D). The bone density in both the lumbus and collum femoris of animals in the MM group was much lower compared with the BD in the MSC, L-PAM, or Control groups (P < 0.05). Although lower than the Control group (P <0.05), no significant differences were observed between the two treated groups (P >0.05).
In addition, MM cell metastasis was determined and quantified in the lungs and kidneys of MM model mice after 4 weeks of feeding (for each group, n = 5) (Figure 1E). The rate of metastasis in the lung tissue obtained from mice in the MSC group was much lower compared with either the MM or the L-PAM groups (P <0.05). Similarly, no significant difference was observed among the MM, MSC, and L-PAM groups in kidney tissue, although the metastasis rate in the MSC group was lowest (P <0.05).
Effects of MSCs on multiple myeloma cells under co-culture conditions
To determine whether the reduction was induced through MM cell apoptosis, caspase-3 and caspase-8 expression in MMs was determined through western blotting. The increased expression of cleaved caspase-3 and caspase-8 was observed in most MM cells after 12 hours of co-culture (Figure 2B). The cleaved caspase-3 and caspase-8 expression in MM cells without co-culture with MSCs was fixed, while the expression of cleaved caspase-3 and caspase-8 in MM cells co-cultured with MSCs was slightly increased. Furthermore, the apoptotic rate of MM cells was examined using fluorescence-activated cell sorting and Annexin V and 7AAD immunofluorescence. We observed that the apoptotic rate of MM cells, determined and quantified through fluorescence-activated cell sorting analysis, was dramatically changed at 12 hours after co-culture with MSCs (P <0.05) (Figure 2C). In the case of immunofluorescence, the number of positive apoptotic markers in MM cells significantly increased after 6 hours of co-culture (P <0.05) (Figure 2D).
Influence of Fas/Fas ligand pathway on multiple myeloma cell apoptosis
Effects of MSCs with highly expressed Fas ligand on the multiple myeloma model mice
MM is a malignancy of antibody-secreting plasma cells, where B-cell plasmacytomas stimulate osteoclast activity, and hence bone resorption, resulting in progressive osteolytic lesions . Based on studies concerning the pathogenic role of autoantibodies in MM diseases, recent advances in this field suggest a more central role for B cells in the maintenance of the disease process beyond their roles as precursors for (auto)antibody-producing plasma cells . Particularly, a number of surface molecules and subsequent downstream signaling pathways are involved in the regulation of MM-related bone destroying events, in which bone resorption and formation are no longer balanced as a consequence of the increased activity of osteoclasts, but rather the osteoblast activity is reduced, leading to an uncoupled, or severely imbalanced, bone remodeling process . Clinical data have shown that MM patients with advanced bone lesions might show a reduction of bone formation markers, such as alkaline phosphatase and osteocalcin, together with increased bone resorption markers, such as receptor activator of nuclear factor κB ligand (RANKL) and C-terminal cross-linked telopeptide of type I collagen . Similarly, marked osteoblastopenia and reduced bone formation have also been reported in murine models of MM bone disease . These studies demonstrate that MM cells suppress osteoblast formation and differentiation, and consequently inhibit bone formation.
Recent mounting evidence indicates that MM cells suppress osteoblastogenesis through contact-dependent cell–cell interaction [7, 34] and the production of osteoblast-inactivating factors including Wnt inhibitors, such as dickkopf-1  and secreted frizzled-related protein 2 , and cytokines, such as CCL3 (also known as macrophage inflammatory protein-1 alpha) , hepatocyte growth factor, and IL-3/6 . Osteolytic lesions in MM are only observed adjacent to intramedullary plasma cell foci or plasmacytomas, supporting the idea that MM cells might secrete factors that promote the activation of osteoclasts and the inactivation of osteoblast function to replace bone loss . More effective approaches to cure MM-related bone disease, in addition to the correction of osteoblast function, should therefore be reflected in therapeutic modalities aimed at inducing MM cell death.
Researchers in the stem cell field are working to translate the knowledge gained from stem cell biology and function into therapeutic breakthroughs and applications. It is well known that osteoblasts originate primarily from MSCs and are responsible for bone matrix synthesis through the secretion of collagen, which forms strands called osteoid . Osteoclast activity is regulated through the expression of cytokines, such as receptor activator of RANKL, which activates osteoclast differentiation, and osteoprotegerin, which acts as a decoy receptor and inhibits RANKL . Based on this knowledge, MSC-based cytotherapy has established a novel concept for the treatment of MM-related bone disease . Recently, Li and colleagues demonstrated that both systemic and intrabone cytotherapeutic strategies were effective and clinically applicable for treating MM-related bone disease , where weekly systemic injections of MSCs restrained MM disease progression through the ability of MSCs to traffic to myelomatous bone and survive for a short period of time . Intrabone injections of MSCs, however, not only inhibited tumor growth in the bone with active MM but also effectively promoted bone formation during disease, remission and delayed MM relapse. Although this study provides a proof-of-concept for the use of MSC cytotherapy to treat large, unhealed, osteolytic lesions and for the systemic inhibition of MM bone disease, the mechanisms of action by which MSC cytotherapy stimulates bone formation and inhibits MM-induced bone tumor growth, are, however, only partially understood . Whether MSCs inhibit or promote cancer growth has developed into a controversy reflected in concern over the use of MSCs, which exhibit a propensity to home to tumors. Once resident in the tumor microenvironment, these cells support tumor growth and spread , although the ability of cultured MSCs to support long-term growth of primary MM cells is often limited and not reproducible [40, 41]. Therefore, understanding the in vivo milieu in which MSCs either inhibit or enhance MM cell survival and metastasis is crucial both to safely develop MSCs as a therapeutic tool and to advance our understanding of the role of tumor stroma in carcinogenesis [16, 17]. Moreover, we still do not have a general consensus of what defines these MSCs; the polarization of MSCs into a proinflammatory or an immunosuppressive phenotype showing reversed effects on tumor growth has been observed [17, 42]. Similarly, in our present study, Fas-Lhigh MSCs showed significant inhibition, while Fas-Lnull MSCs showed promoted MM growth, suggesting that the levels of Fas-L expression in MSCs determine, at least in part, the effect of MSCs on cancer growth.
Recent findings suggest that the overexpression of growth differentiation factor 15 in bone marrow MSCs occurs widely in patients with MM, and tumor microenvironment-derived growth differentiation factor 15 is a key survival and chemoprotective factor for MM cells, indicating that the behavior of MSCs might be principally determined by the surrounding environment . The two side effects of MSCs on MM cells identified from previous studies are therefore basically acceptable. To further clarify the role of healthy MSCs in MM metastasis and apoptosis, we examined whether outside-infused MSCs would have therapeutic effects on MM cells in mice under co-culture conditions. The data obtained in the present study are clearly inconsistent with some reports, which have indicated that murine and human MSCs promote breast and coronal cancer growth and metastasis [44, 45]. Interestingly, Ma and colleagues showed that human umbilical cord MSCs significantly inhibited the growth of breast cancer cells in vitro and in vivo. Furthermore, the ability of cytotherapy through placenta-derived adherent cells to impact bone remodeling and increase bone formation in nonmyelomatous SCID-rab mice has been demonstrated . Intralesional mesenchymal cell cytotherapy also resulted in inhibiting growth of H929 MM cells and primary MM cells categorized through global gene expression as high risk. Moreover, placenta-derived adherent cells had no effect on the subcutaneous growth of H929 MM cells in SCID mice, and did not confer a growth advantage to MM cells co-cultured with placenta-derived adherent cells or supportive MSCs . Recently, adipose-derived MSCs, engineered to express the pro-apoptotic ligand TRAIL (also known as TNFSF10), killed MM cells and migrated towards MM cells in vitro. These results, together with data in the present study, support the idea that certain phenotypes of MSCs exhibit inhibitory effects on MM cells, such that the anti-myeloma activity of MSCs can be harnessed or enhanced, for example, via gene-modified approaches.
It has been well recognized that MSC therapy potentially offers novel therapeutic modalities that are translatable for clinical treatment of a large variety of pathological conditions or diseases . This development is also true for clinically managing and combating cancer, as MSCs play a central role in the pathogenesis and progression of tumors [5, 50]. MSC administration thus reduces solid tumor growth in mice due to an inhibition of tumor cell proliferation, probably resulting from deep modifications of the tumor angiogenesis, regardless of the tumor model and mode of MSC injection . Clinically, current evidence suggests that cytotherapy markedly increases the proportion of MSCs in bone of MM patients, at least for a short period of time [5, 15]. As deduced from in vitro studies, during this short time, the injected MSCs probably interact with endogenous osteoblast precursors and secrete factors that induce their differentiation into bone-building osteoblasts, while simultaneously directly interactions with osteoclast precursors to secrete factors that attenuate the formation of bone-resorbing osteoclasts . Notably, similar to osteoblasts, MSCs might produce a high level of decorin protein, which inhibits osteoclast formation and promotes osteoblast differentiation . Following the identification of the potential for MSCs to enhance engraftment of hematopoietic stem cells, increase osteoblast activity and suppress osteoclast activity , MSCs recruited hematopoietic elements that inhibit inflammatory conditions typically associated with MM growth in bone . Along with recent findings in this field [17, 42], it is speculated that MM progression is restrained, directly and indirectly, through anti-inflammatory factors produced by the injected MSCs or endogenous cells recruited to myelomatous bone after cytotherapy. The findings that MSCs express high levels of anti-inflammatory and antineoplastic factors, such as SERPINF1 and decorin, support this concept . Decorin also attenuates MM cell growth . Although certain soluble factors produced by MSCs might mediate part of their therapeutic activities, cytotherapy at a remote site (subcutaneous) was found to have no effect on MM bone disease or growth , suggesting that MSCs must be present in bone marrow to elicit their antimyeloma effects. Indeed, only MSCs injected directly into bone might efficiently induce an antimyeloma environment. Systemically injected MSCs significantly promote bone formation or restrain MM growth because relatively few of those MSCs can transmigrate and traffic to bone . Recent results, however, also suggest that MSCs might be attracted to bone through MM cells or conditions induced through MM or melphalan treatment. More importantly, MSCs might be cleared in various tissues, but exhibit higher survival rates in the implanted bone or lymph nodes and therefore could be detected in these tissues at 2 to 3 days after intravenous or intracardiac injections, respectively . The accumulation of MSCs in lymph nodes, however, might partially explain their immunomodulatory properties. In fact, evidence suggests that intravenously injected MSCs might localize in the lymph nodes of experimental mouse models of autoimmunity [53, 54]. This body of work might also explain the fewer numbers and smaller sizes of cancroid pearls in the neck and root tail of the MSC-treated MM mice in the present study.
Recent studies have revealed that exogenously injected MSCs were not detectable in vivo for long periods of time; the majority of these cells disappeared within 3 to 5 weeks [15, 55]. Clinically, this phenomenon might be advantageous because it limits the duration of the intervention, and these observations support the notion that most of their activities are mediated through the touch-and-go mechanisms of bystander cells, although proof of such evanescence is thus far not well defined [5, 56]. In support of using allogeneic MSCs for MM, Li and colleagues recently demonstrated that intralesionally injected human placenta mesenchymal cells exert similar therapeutic effects in SCID-rab mice . Together, these studies raise an intriguing possibility: if we could understand how MSCs induce MM cell death, then perhaps we could exogenously manipulate MSCs to effectively manage MM and saved a large number of lives. An important, yet unelucidated, question raised by our study is whether a majority of MSCs transmigrate to the myelomatous bone to kill MM cells after intravenous injection, or traffic to lymph nodes to exert inhibitory effects on MM cells via the secretion of anti-inflammatory factors.
The potential role of molecules involved in altered B-cell longevity, particularly those involved in apoptosis (for example, Fas/Fas-L modulators), and those that might alter activation thresholds of B cells in the development of autoimmunity, might contribute to the clinical management of MM [27, 31]. Unfortunately, however, we still know relatively little about this issue. Recently, a number of studies have reported the effects of the Fas/Fas-L pathway on fluoride-induced or melatonin-induced cell apoptosis [57, 58]. In the present study, it was shown that MSCs counterattack MM cells using the same mechanism as observed in other cancer cells; namely, Fas-mediated apoptosis. Fas and Fas-L are co-expressed on primary MSCs that might kill co-cultured MM cells. Co-expression of Fas and Fas-L by MSCs calls into question the functionality of the extrinsic apoptosis pathway in these cells. Although Mazar and colleagues detected Fas expression on MSCs, stimulation of Fas with different concentrations of anti-Fas antibody did not result in any apoptotic response . At this stage, we were not able to identify the exact molecular mechanism of Fas-mediated pathway inactivation in MSCs, but we might narrow this process to events between Fas protein trimerization and caspase-8 activation. As previously demonstrated, caspase-8 deficiency resulted in the inhibition of apoptosis of Jurkat cells, and blocking with Fas Fc protein prevented bone marrow MSC-induced apoptosis in 80% . Other studies have shown that the transformation of the intracellular domain of Fas protein expressed in human MSCs prevents the trimerization of the receptor and blocks the activation of apoptotic pathway activation . MM cells might thus be susceptible to the induction of apoptosis through MSCs.
Briefly, we showed that MSCs act directly on MM cells, inhibiting proliferation. MSC-induced apoptosis in MM cells is evidenced by an increase in the Annexin/7AAD-positive cell population. Most of this effect can be attributed to the Fas/Fas-L pathway. These results confirm and extend previous reports [60, 61]. In our MM model, the activation of both caspase-3 and caspase-8 was observed, suggesting that two main pathways of procaspase activation – the intrinsic mitochondrial pathway and the extrinsic death receptor pathway – are both involved in MSC-induced apoptosis of MM. Having determined the effects of MSCs activated through aspirin (with highly activated Fas-L) in the MM model mice, these MSCs resulted in a more effective clinical outcome compared with MSCs from the gld mice. We thus expected that MSCs with high Fas-L expression would be extremely effective in inhibiting MM growth and metastasis. These results are consistent in principle with those of another study, showing that infused MSCs moved immediately to the tumor site . However, the positive TUNEL reactions within MSCs from the gld mice were much lower than the others, suggesting that MSCs without Fas-L have no capacity to kill MM cells.
Fas-L is expressed on MSCs to induce MM cell apoptosis under co-culture conditions. Furthermore, Fas-L activated through aspirin effectively inhibits the growth and metastasis of MMs in vitro and in vivo. Our results showed the additive or synergistic anti-MM activity of MSCs with highly activated Fas-L, measured on the basis of cell growth, apoptosis, and modest survival improvement of MM-bearing mice, indicating that the levels of Fas-L expression in MSCs determine, at least partially, the effect of MSCs on cancer growth. Our finding has opened up a new way of thinking about the effect of MSCs against MM cells and a new way of moving forward. Further research should aim at improving the trafficking of infused MSCs to myelomatous bone, clarifying and increasing the anti-inflammatory therapeutic potential of these cells during active disease or maintenance therapy compared with the typical administration of drugs, such as L-PAM.
IA and SL are co-first authors. SS and F-MC are co-last authors.
Generalized lymphoproliferative disease
Lymphocyte Peyer’s patch adhesion molecules
Mesenchymal stromal cell
Receptor activator of nuclear factor κB ligand
Tumor necrosis factor
Terminal deoxynucleotidyl transferase-mediated UTP nick-end labeling.
This work was supported through grants from the National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services (R01DE017449 and R01DE019932), the National Natural Science Foundation of China (31170912), and the Program for New Century Excellent Talents in University (NCET-12-1005).
- Bergsagel PL, Kuehl WM: Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005, 23: 6333-6338. 10.1200/JCO.2005.05.021.View ArticlePubMedGoogle Scholar
- Yaccoby S: Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol. 2010, 149: 311-321. 10.1111/j.1365-2141.2010.08141.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Giuliani N, Rizzoli V, Roodman GD: Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood. 2006, 108: 3992-3996. 10.1182/blood-2006-05-026112.View ArticlePubMedGoogle Scholar
- Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ: Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007, 25: 1121-1128. 10.1200/JCO.2006.08.5803.View ArticlePubMedGoogle Scholar
- Li X, Ling W, Khan S, Yaccoby S: Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth. J Bone Miner Res. 2012, 27: 1635-1648. 10.1002/jbmr.1620.PubMed CentralView ArticlePubMedGoogle Scholar
- Jemal A, Graubard BI, Devesa SS, Flegal KM: The association of blood lead level and cancer mortality among whites in the United States. Environ Health Perspect. 2002, 110: 325-329. 10.1289/ehp.02110325.PubMed CentralView ArticlePubMedGoogle Scholar
- Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, Grano M, Colucci S, Svaldi M, Rizzoli V: Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 2005, 106: 2472-2483. 10.1182/blood-2004-12-4986.View ArticlePubMedGoogle Scholar
- Li X, Pennisi A, Yaccoby S: Role of decorin in the antimyeloma effects of osteoblasts. Blood. 2008, 112: 159-168. 10.1182/blood-2007-11-124164.PubMed CentralView ArticlePubMedGoogle Scholar
- Giuliani N, Mangoni M, Rizzoli V: Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets. Exp Hematol. 2009, 37: 879-886. 10.1016/j.exphem.2009.04.004.View ArticlePubMedGoogle Scholar
- Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD: Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007, 109: 2106-2111. 10.1182/blood-2006-09-047712.PubMed CentralView ArticlePubMedGoogle Scholar
- Vallet S, Pozzi S, Patel K, Vaghela N, Fulciniti MT, Veiby P, Hideshima T, Santo L, Cirstea D, Scadden DT, Anderson KC, Raje N: A novel role for CCL3 (MIP-1alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia. 2011, 25: 1174-1181. 10.1038/leu.2011.43.PubMed CentralView ArticlePubMedGoogle Scholar
- Gasparetto C: Stem cell transplantation for multiple myeloma. Cancer Control. 2004, 11: 119-129.PubMedGoogle Scholar
- Suzuki K, Sun R, Origuchi M, Kanehira M, Takahata T, Itoh J, Umezawa A, Kijima H, Fukuda S, Saijo Y: Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med. 2011, 17: 579-587.PubMed CentralView ArticlePubMedGoogle Scholar
- Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F: Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?. Stem Cells. 2011, 29: 11-19. 10.1002/stem.559.PubMed CentralView ArticlePubMedGoogle Scholar
- Li X, Ling W, Pennisi A, Wang Y, Khan S, Heidaran M, Pal A, Zhang X, He S, Zeitlin A, Abbot S, Faleck H, Hariri R, Shaughnessy JD, van Rhee F, Nair B, Barlogie B, Epstein J, Yaccoby S: Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cells. 2011, 29: 263-273. 10.1002/stem.572.View ArticlePubMedGoogle Scholar
- Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, Yaccoby S, Xiong W, Barlogie B, Shaughnessy JD, Zhan F: Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood. 2010, 115: 61-70. 10.1182/blood-2009-03-210526.PubMed CentralView ArticlePubMedGoogle Scholar
- Waterman RS, Henkle SL, Betancourt AM: Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PLoS One. 2012, 7: e45590-10.1371/journal.pone.0045590.PubMed CentralView ArticlePubMedGoogle Scholar
- Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA: A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2006, 24: 986-991. 10.1634/stemcells.2005-0220.View ArticlePubMedGoogle Scholar
- Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, Tschopp J, Wajant H, Wallach D, Wiltrout RH, Zörnig M, Lynch DH: The CD95 receptor: apoptosis revisited. Cell. 2007, 129: 447-450. 10.1016/j.cell.2007.04.031.View ArticlePubMedGoogle Scholar
- Strasser A, Jost PJ, Nagata S: The many roles of Fas receptor signalling in the immune system. Immunity. 2009, 30: 180-192. 10.1016/j.immuni.2009.01.001.PubMed CentralView ArticlePubMedGoogle Scholar
- Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993, 75: 1169-1178. 10.1016/0092-8674(93)90326-L.View ArticlePubMedGoogle Scholar
- Lettau M, Paulsen M, Kabelitz D, Janssen O: Storage, expression and function of Fas ligand, the key death factor of immune cells. Curr Med Chem. 2008, 15: 1684-1696. 10.2174/092986708784872384.View ArticlePubMedGoogle Scholar
- Mazar J, Thomas M, Bezrukov L, Chanturia A, Pekkurnaz G, Yin S, Kuznetsov SA, Robey PG, Zimmerberg J: Cytotoxicity mediated by the Fas ligand (FasL)-activated apoptotic pathway in stem cells. J Biol Chem. 2009, 284: 22022-22028. 10.1074/jbc.M109.032235.PubMed CentralView ArticlePubMedGoogle Scholar
- LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002, 62: 4996-5000.PubMedGoogle Scholar
- Liu Y, Wang L, Kikuiri T, Akiyama K, Chen C, Xu X, Yang R, Chen W, Wang S, Shi S: Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nat Med. 2011, 17: 1594-1601. 10.1038/nm.2542.PubMed CentralView ArticlePubMedGoogle Scholar
- Oyajobi BO, Franchin G, Williams PJ, Pulkrabek D, Gupta A, Munoz S, Grubbs B, Zhao M, Chen D, Sherry B, Mundy GR: Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood. 2003, 102: 311-319. 10.1182/blood-2002-12-3905.View ArticlePubMedGoogle Scholar
- Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, Cai T, Chen W, Sun L, Shi S: Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell. 2012, 10: 544-555. 10.1016/j.stem.2012.03.007.PubMed CentralView ArticlePubMedGoogle Scholar
- Musto P, D’Auria F: Melphalan: old and new uses of a still master drug for multiple myeloma. Expert Opin Investig Drugs. 2007, 16: 1467-1487. 10.1517/135437126.96.36.1997.View ArticlePubMedGoogle Scholar
- Zhang Q, Shi S, Liu Y, Uyanne J, Shi Y, Shi S, Le AD: Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol. 2009, 183: 7787-7798. 10.4049/jimmunol.0902318.PubMed CentralView ArticlePubMedGoogle Scholar
- Sun LY, Zhou KX, Feng XB, Zhang HY, Ding XQ, Jin O, Lu LW, Lau CS, Hou YY, Fan LM: Abnormal surface markers expression on bone marrow CD34+ cells and correlation with disease activity in patients with systemic lupus erythematosus. Clin Rheumatol. 2007, 26: 2073-2079. 10.1007/s10067-007-0621-2.View ArticlePubMedGoogle Scholar
- Dörner T, Lipsky PE: Signalling pathways in B cells: implications for autoimmunity. Curr Top Microbiol Immunol. 2006, 305: 213-240.PubMedGoogle Scholar
- Vejlgaard T, Abildgaard N, Jans H, Nielsen JL, Heickendorff L: Abnormal bone turnover in monoclonal gammaopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens. Eur J Haematol. 1997, 58: 104-108.View ArticlePubMedGoogle Scholar
- Hjorth-Hansen H, Seifert MF, Börset M, Aarset H, Ostlie A, Sundan A, Waage A: Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res. 1999, 14: 256-263. 10.1359/jbmr.19188.8.131.526.View ArticlePubMedGoogle Scholar
- Pennisi A, Ling W, Li X, Khan S, Shaughnessy JD, Barlogie B, Yaccoby S: The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood. 2009, 114: 1803-1812. 10.1182/blood-2009-01-201954.PubMed CentralView ArticlePubMedGoogle Scholar
- Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, Kido S, Inoue D, Matsumoto T: Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005, 106: 3160-3165. 10.1182/blood-2004-12-4940.View ArticlePubMedGoogle Scholar
- Bataille R, Manolagas SC, Berenson JR: Pathogenesis and management of bone lesions in multiple myeloma. Hematol Oncol Clin North Am. 1997, 11: 349-361. 10.1016/S0889-8588(05)70435-4.View ArticlePubMedGoogle Scholar
- Gregory CA, Gunn WG, Reyes E, Smolarz AJ, Munoz J, Spees JL, Prockop DJ: How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow. Ann N Y Acad Sci. 2005, 1049: 97-106. 10.1196/annals.1334.010.View ArticlePubMedGoogle Scholar
- Glass DA, Patel MS, Kassenty G: A new insight into the formation of osteolytic lesions in multiple myeloma. N Engl J Med. 2003, 349: 2479-2480. 10.1056/NEJMp038176.View ArticlePubMedGoogle Scholar
- Fu J, Wang P, Zhang X, Ju S, Li J, Li B, Yu S, Zhang J, Zhang X: Myeloma cells inhibit osteogenic differentiation of mesenchymal stem cells and kill osteoblasts via TRAIL-induced apoptosis. Arch Med Sci. 2010, 6: 496-504.PubMed CentralView ArticlePubMedGoogle Scholar
- Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, Munshi NC, Anderson KC: The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007, 21: 1007-1034. 10.1016/j.hoc.2007.08.007. vii–viiiView ArticlePubMedGoogle Scholar
- Wang X, Zhang Z, Yao C: Survivin is upregulated in myeloma cell lines cocultured with mesenchymal stem cells. Leuk Res. 2010, 34: 1325-1329. 10.1016/j.leukres.2010.05.006.View ArticlePubMedGoogle Scholar
- Coffelt SB, Marini FC, Watson K, Zwezdaryk KJ, Dembinski JL, LaMarca HL, Tomchuck SL, Honer ZU, Bentrup K, Danka ES, Henkle SL, Scandurro AB: The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci USA. 2009, 106: 3806-3811. 10.1073/pnas.0900244106.PubMed CentralView ArticlePubMedGoogle Scholar
- Corre J, Labat E, Espagnolle N, Hébraud B, Avet-Loiseau H, Roussel M, Huynh A, Gadelorge M, Cordelier P, Klein B, Moreau P, Facon T, Fournié JJ, Attal M, Bourin P: Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res. 2012, 72: 1395-1406. 10.1158/0008-5472.CAN-11-0188.View ArticlePubMedGoogle Scholar
- Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, Higashi Y, Tanaka S, Yasui W, Chayama K: Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer. 2010, 127: 2323-2333. 10.1002/ijc.25440.View ArticlePubMedGoogle Scholar
- Albarenque SM, Zwacka RM, Mohr A: Both human and mouse mesenchymal stem cells promote breast cancer metastasis. Stem Cell Res. 2011, 7: 163-171. 10.1016/j.scr.2011.05.002.View ArticlePubMedGoogle Scholar
- Ma Y, Hao X, Zhang S, Zhang J: The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells. Breast Cancer Res Treat. 2012, 133: 473-485. 10.1007/s10549-011-1774-x.View ArticlePubMedGoogle Scholar
- Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zallone AZ, Marchisio PC: Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood. 1991, 77: 2688-2693.PubMedGoogle Scholar
- Ciavarella S, Grisendi G, Dominici M, Tucci M, Brunetti O, Dammacco F, Silvestris F: In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. Br J Haematol. 2012, 157: 586-598. 10.1111/j.1365-2141.2012.09082.x.View ArticlePubMedGoogle Scholar
- Chen FM, Zhao YM, Jin Y, Shi S: Prospects for translational regenerative medicine. Biotechnol Adv. 2012, 30: 658-672. 10.1016/j.biotechadv.2011.11.005.View ArticlePubMedGoogle Scholar
- Gomes CM: The dual role of mesenchymal stem cells in tumor progression. Stem Cell Res Ther. 2013, 4: 42-10.1186/scrt189.PubMed CentralView ArticlePubMedGoogle Scholar
- Kéramidas M, de Fraipont F, Karageorgis A, Moisan A, Persoons V, Richard MJ, Coll JL, Rome C: The dual effect of mesenchymal stem cells on tumour growth and tumour angiogenesis. Stem Cell Res Ther. 2013, 4: 41-10.1186/scrt195.PubMed CentralView ArticlePubMedGoogle Scholar
- Prather WR, Toren A, Meiron M: Placental-derived and expanded mesenchymal stromal cells (PLX-I) to enhance the engraftment of hematopoietic stem cells derived from umbilical cord blood. Expert Opin Biol Ther. 2008, 8: 1241-1250. 10.1517/147125184.108.40.2061.View ArticlePubMedGoogle Scholar
- Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A: Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005, 106: 1755-1761. 10.1182/blood-2005-04-1496.View ArticlePubMedGoogle Scholar
- Parekkadan B, Tilles AW, Yarmush ML: Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells. 2008, 26: 1913-1919. 10.1634/stemcells.2007-0790.View ArticlePubMedGoogle Scholar
- Prockop DJ: Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther. 2009, 17: 939-946. 10.1038/mt.2009.62.PubMed CentralView ArticlePubMedGoogle Scholar
- Uccelli A, Moretta L, Pistoia V: Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008, 8: 726-736. 10.1038/nri2395.View ArticlePubMedGoogle Scholar
- Xu B, Xu Z, Xia T, He P, Gao P, He W, Zhang M, Guo L, Niu Q, Wang A: Effects of the Fas/Fas-L pathway on fluoride-induced apoptosis in SH-SY5Y cells. Environ Toxicol. 2011, 26: 86-92. 10.1002/tox.20543.View ArticlePubMedGoogle Scholar
- García-Santos G, Martin V, Rodríguez-Blanco J, Herrera F, Casado-Zapico S, Sánchez-Sánchez AM, Antolín I, Rodríguez C: Fas/Fas ligand regulation mediates cell death in human Ewing’s sarcoma cells treated with melatonin. Br J Cancer. 2012, 106: 1288-1296. 10.1038/bjc.2012.66.PubMed CentralView ArticlePubMedGoogle Scholar
- O’Connell J, Houston A, Bennett MW, O’Sullivan GC, Shanahan F: Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med. 2012, 7: 271-274. 2001View ArticleGoogle Scholar
- Yang X, Yang C, Shao K, Ye X, Meng H, Zhou Y, Qian W: Refractory multiple myeloma treated with homoharringtonine: report of two cases. Ann Hematol. 2007, 86: 919-921. 10.1007/s00277-007-0331-5.View ArticlePubMedGoogle Scholar
- Lou YJ, Qian WB, Jin J: Homoharringtonine induces apoptosis and growth arrest in human myeloma cells. Leuk Lymphoma. 2007, 48: 1400-1406. 10.1080/10428190701411466.View ArticlePubMedGoogle Scholar
- Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T: Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med. 2006, 203: 1235-1247. 10.1084/jem.20051921.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.